Soloway M S
Department of Urology, University of Tennessee, Memphis.
Cancer. 1990 Sep 1;66(5 Suppl):1017-21. doi: 10.1002/cncr.1990.66.s5.1017.
Three factors were identified in a multivariate analysis of prognostic factors in men with metastatic prostate cancer as significantly associated with their progression-free survival: 1) extent of disease on the bone scan, 2) pretreatment serum testosterone, and 3) performance status. Men with less than six bone metastases, a pretreatment testosterone greater than 300 ng/100 ml, and an excellent performance status will have a progression-free survival much longer than a man with more extensive bone metastases, a low testosterone prior to androgen deprivation, and a poor performance status. This information should be used to ensure proper stratification in randomized trials. It may also be helpful in identifying the patient unlikely to be helped by our current treatment. Such patients should be considered for alternative approaches with the aim of improving survival.
在一项对转移性前列腺癌男性患者预后因素的多变量分析中,确定了三个与无进展生存期显著相关的因素:1)骨扫描的疾病范围;2)治疗前血清睾酮水平;3)体能状态。骨转移少于六个、治疗前睾酮水平大于300 ng/100 ml且体能状态良好的男性患者,其无进展生存期将比骨转移范围更广、去势前睾酮水平低且体能状态差的男性患者长得多。这些信息应在随机试验中用于确保适当的分层。它也可能有助于识别那些不太可能从我们目前的治疗中获益的患者。应考虑为这类患者采用替代方法,以提高生存率。